CO2023003009A2 - Anticuerpos multiespecíficos anti-tcr delta variable 1 - Google Patents

Anticuerpos multiespecíficos anti-tcr delta variable 1

Info

Publication number
CO2023003009A2
CO2023003009A2 CONC2023/0003009A CO2023003009A CO2023003009A2 CO 2023003009 A2 CO2023003009 A2 CO 2023003009A2 CO 2023003009 A CO2023003009 A CO 2023003009A CO 2023003009 A2 CO2023003009 A2 CO 2023003009A2
Authority
CO
Colombia
Prior art keywords
antibodies
bispecific
antigen
bind
cell
Prior art date
Application number
CONC2023/0003009A
Other languages
English (en)
Spanish (es)
Inventor
Mark Uden
Mihriban Tuna
Natalie Mount
Robert Good
Joshua Freedman
Shefali Bhumbra
Oliver Nussbaumer
Raj Jaysukhlal Mehta
Original Assignee
Gammadelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2023003009(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd
Publication of CO2023003009A2 publication Critical patent/CO2023003009A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
CONC2023/0003009A 2020-08-14 2023-03-13 Anticuerpos multiespecíficos anti-tcr delta variable 1 CO2023003009A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (1)

Publication Number Publication Date
CO2023003009A2 true CO2023003009A2 (es) 2023-03-17

Family

ID=80247426

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0003009A CO2023003009A2 (es) 2020-08-14 2023-03-13 Anticuerpos multiespecíficos anti-tcr delta variable 1

Country Status (18)

Country Link
EP (7) EP4265642B1 (https=)
JP (1) JP7847579B2 (https=)
KR (1) KR20230083267A (https=)
CN (1) CN116209456A (https=)
AU (1) AU2021323512A1 (https=)
BR (1) BR112023002741A2 (https=)
CA (1) CA3188682A1 (https=)
CO (1) CO2023003009A2 (https=)
DK (2) DK4010082T4 (https=)
ES (2) ES2943063T3 (https=)
FI (2) FI4010082T4 (https=)
IL (1) IL300517A (https=)
LT (2) LT4010082T (https=)
MX (1) MX2023001728A (https=)
PL (2) PL4269444T3 (https=)
PT (2) PT4010082T (https=)
SI (2) SI4010082T1 (https=)
WO (1) WO2022034562A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
WO2023250485A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
WO2024193459A1 (en) * 2023-03-17 2024-09-26 Nanjing Legend Biotech Co., Ltd. METHODS OF CULTURING Vδ1 T CELLS
WO2025147597A1 (en) * 2024-01-05 2025-07-10 Eugit Therapeutics, Inc. Targeting payloads
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US20180028566A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
EP3645050A4 (en) 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
AU2019344300A1 (en) * 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
US12084500B2 (en) * 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies

Also Published As

Publication number Publication date
EP4269446B1 (en) 2024-06-26
EP4265643B1 (en) 2024-06-26
JP7847579B2 (ja) 2026-04-17
AU2021323512A1 (en) 2023-04-13
PT4269444T (pt) 2024-09-05
EP4010082A1 (en) 2022-06-15
LT4010082T (lt) 2023-03-10
ES2993071T3 (en) 2024-12-20
DK4269444T3 (en) 2024-08-19
EP4265643A2 (en) 2023-10-25
FI4010082T4 (fi) 2026-03-24
EP4265642B1 (en) 2024-06-26
FI4010082T3 (fi) 2023-04-04
EP4218932A2 (en) 2023-08-02
EP4269446A3 (en) 2024-02-14
PL4269444T3 (pl) 2025-01-13
PL4010082T5 (pl) 2026-03-09
DK4010082T5 (da) 2024-08-05
CA3188682A1 (en) 2022-02-17
EP4265643A3 (en) 2024-02-14
EP4010082B2 (en) 2025-12-31
PL4010082T3 (pl) 2023-05-29
SI4269444T1 (sl) 2024-10-30
EP4265642A3 (en) 2024-02-14
EP4010082B1 (en) 2023-01-25
FI4269444T3 (fi) 2024-09-20
DK4269444T5 (da) 2024-08-26
ES2943063T3 (es) 2023-06-08
EP4218932A3 (en) 2023-09-27
LT4269444T (lt) 2024-09-25
EP4265642A2 (en) 2023-10-25
EP4269444A3 (en) 2024-02-14
WO2022034562A1 (en) 2022-02-17
DK4010082T3 (da) 2023-04-03
KR20230083267A (ko) 2023-06-09
EP4269445B1 (en) 2024-06-26
SI4010082T1 (sl) 2023-04-28
DK4010082T4 (en) 2026-02-16
EP4269445A2 (en) 2023-11-01
BR112023002741A2 (pt) 2023-10-10
EP4010082B9 (en) 2026-03-04
EP4269444B1 (en) 2024-06-26
MX2023001728A (es) 2023-04-20
IL300517A (en) 2023-04-01
EP4269444A2 (en) 2023-11-01
EP4269446A2 (en) 2023-11-01
EP4269445A3 (en) 2024-02-14
JP2023537534A (ja) 2023-09-01
CN116209456A (zh) 2023-06-02
PT4010082T (pt) 2023-04-26

Similar Documents

Publication Publication Date Title
CO2023003009A2 (es) Anticuerpos multiespecíficos anti-tcr delta variable 1
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
MX2020014158A (es) Anticuerpos anti proteína de muerte programada 1 (pd-1) y usos de estos.
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
SA520411577B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CL2022003449A1 (es) Captadores de células inmunitarias biespecíficas con especificidad de unión para hla-g y otro antígeno
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
MX2023011788A (es) Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
CO2019010024A2 (es) Anticuerpos biespecíficos anti-pd-l1-anti-tim-3
CO2022013633A2 (es) Anticuerpos novedosos
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
MX2024006205A (es) Composiciones que comprenden agentes de unión multiespecíficos potenciados para una respuesta inmunitaria.
JOP20250161A1 (ar) الأجسام المضادة لـ unc5c
FR3042122B1 (fr) Composition anti-tumorale
MX2025002390A (es) Metodos para el tratamiento del cancer utilizando anticuerpos anti- ctla4
UY37915A (es) Anticuerpos específicos para cd47 y pd-l1
AR117660A1 (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
Rial et al. New evidence from the Devonian dispersed spore record of the Iberian Peninsula: implications in our conception of the Rheic Ocean